Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
27 Cards in this Set
- Front
- Back
BRAND NAME:
Adalimumab |
Humira
|
|
INDICATIONS:
Adalimumab |
-Ankylosing spondylitis
-Crohn's Disease -Plaque psoriasis -Psoriatic arthritis -RA -Ulcerative colitis |
|
THERAPEUTIC CLASS:
Adalimumab |
TNF-alpha inhibitor
|
|
SIDE EFFECTS:
Adalimumab |
-Headache
-Rash -Positive ANA titer -Antibody development -Serious infection -Injection site reactions -Increased CPK -URI, sinusitis |
|
BLACK BOX WARNING:
Adalimumab |
Patients treated with adalimumab are AT INCREASED RISK FOR INFECTIONS, some progressing to serious infections leading to hospitalization or death. These infections have included bacterial sepsis, tuberculosis, invasive fungal, and other opportunistic infections including Legionella and Listeria.
Evaluate for latent tuberculosis and treat if necessary prior to initiation of therapy. LYMPHOMA and other MALIGNANCIES, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, of which adalimumab is a member Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), usually fatal, have been reported in patients treated with TNF blockers including adalimumab, primarily in adolescent and young adult males with Crohn's disease and ulcerative colitis. Most of these cases of HSTCL occurred in patients receiving concomitant treatment with azathioprine or 6-mercaptopurine [2]. |
|
DRUG DRUG INTERACTIONS:
Adalimumab |
-Live vaccines (C/I)
-Tacrolimus (decreased tacrolimus exposure) -Cyclosporine (decreased cyclosporine exposure) -Abatacept, anakinra (increased risk of infections) |
|
BRAND NAME:
Atovaquone |
Mepron
|
|
INDICATIONS:
Atovaquone |
-Pneumocystis pneumonia (PCP) - prevention and treatment (mild-to-moderate)
|
|
THERAPEUTIC CLASS:
Atovaquone |
-Antiprotozoal
-Ubiquinone |
|
SIDE EFFECTS:
Atovaquone |
-Rash
-Abdominal pain -N/V/D -Asthenia -Headache -Insomnia -Cough -Dyspnea -Rhinitis -Fever -Infectious disease |
|
COUNSELING POINTS:
Atovaquone |
Take with meals (as reduced absorption may result if taken on an empty stomach).
|
|
DOSAGE FORM:
Atovaquone |
Oral suspension: 750 mg/5 mL
|
|
DRUG DRUG INTERACTIONS:
Atovaquone |
Rifampin (decreased atovaquone plasma concentrations)
|
|
BRAND NAME:
Diltiazem |
Cardizem
Cardizem CD |
|
INDICATIONS:
Diltiazem |
-Atrial arrhythmia
-HTN -Paroxysmal supraventricular tachycardia -Chronic stable angina |
|
THERAPEUTIC CLASS:
Diltiazem |
Calcium channel blocker
|
|
SIDE EFFECTS:
Diltiazem |
-Peripheral edema
-Fatigue -Dizziness -HA |
|
DRUG DRUG INTERACTIONS:
Diltiazem |
-Atazanavir - prolonged PR interval
-Clozapine -Colchicine (increased colchicine concentrations) -Simvastatin (increased simvastatin concentrations; increased risk of myopathy, incl rhabdomyolysis) -Clarithromycin (increased diltiazem exposure) -Clopidogrel (decreased antiplatelet effect and increased risk of thrombotic events) |
|
CONTRAINDICATIONS:
Diltiazem |
-Acute MI w/ pulmonary congestion on xray
-A Fib or flutter associated w/ an accessory bypass tract (Wolff-Parkinson-White or short PR syndromes) - IV only -Cardiogenic shock (IV only) -2nd or 3rd degree AV heart block w/out a functioning pacemaker -Symptomatic hypotension (systolic < 90 mmHg) -Newborns (some injections contain benzyl alcohol) -Sick sinus syndrome w/out a functioning ventricular pacemaker -Ventricular tachycardia (IV only) |
|
BRAND NAME:
Famotidine |
Pepcid
|
|
INDICATIONS:
Famotidine |
-Duodenal ulcer disease
-GERD -Gastric hypersecretion -Gastric ulcer -Indigestion |
|
THERAPEUTIC CLASS:
Famotidine |
H2 blocker
|
|
DRUG DRUG INTERACTIONS:
Famotidine |
-HIV drugs - atazanavir, rilpivirine (decreased concentration of HIV drugs)
|
|
BRAND NAME:
Hydrocodone/APAP |
Vicodin
Lortab Norco |
|
INDICATIONS:
Hydrocodone/APAP |
Moderate to moderate-severe pain
|
|
THERAPEUTIC CLASS:
Hydrocodone/APAP |
Opioid/APAP combo
|
|
SIDE EFFECTS:
Hydrocodone/APAP |
-Constipation
-Dizziness -N/V -Sedation -Urinary retention |